Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer
NCT04300699 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2020-03-09
Summary
Ovarian cancer is frequently diagnosed in older women, with over half of all new diagnoses being in women over 65 years. Current treatment options are based on the results of clinical trials that often do not include older, less fit patients in whom treatments may be less well tolerated. Further, in older patients the impact of complex medical and social issues is not known. The UK lags behind Europe and the United States in the development of research programs dedicated to improving outcomes for older patients. More research focus is urgently required to improve the assessment and management of older women with ovarian cancer to improve survival outcomes, quality of life and functional independence.
Current treatment decisions are made predominantly on age and fitness. However, it has been shown that undertaking a holistic, geriatric assessment of older patients can highlight important issues that would not necessarily be identified in a routine oncology appointment. In this study, we propose to ask oncology teams to undertake a geriatric assessment and specifically address issues that may arise as a result of this. The assessment comprises 8 simple non-invasive assessments that can be performed in the out-patient setting.
This approach could result in an important change in clinical practice leading to more holistic assessment of older cancer patients and better address their specific needs and manage their cancer treatment. The long-term goal is to show that pro-actively managing potential issues at the beginning of treatment allows patients to tolerate treatment and maintain their functional independence, leading to improved quality of life.
Conditions
- Ovarian Cancer
- Chemotherapy
- Quality of Life
- Tolerance
- Aged
Interventions
- OTHER
-
Functional Geriatric Assessment
A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
Sponsors & Collaborators
-
Royal Marsden NHS Foundation Trust
lead OTHER
Principal Investigators
-
Susana Banerjee, MBBS MA FRCP · Royal Marsden NHS Foundation Trust
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-06-01
- Primary Completion
- 2021-12-01
- Completion
- 2022-12-01
More Related Trials
-
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771 ·Status: RECRUITING
-
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
NCT06917469 ·Status: COMPLETED
-
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT01366183 ·Status: UNKNOWN
-
Assessment of Ovarian Reserve in Female Cancer Survivors
NCT01062542 ·Status: COMPLETED
-
The Treatment Preferences of Women Diagnosed With Ovarian Cancer
NCT03367260 ·Status: COMPLETED
-
Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment
NCT05274867 ·Status: UNKNOWN
-
Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR
NCT04295577 ·Status: COMPLETED
-
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
NCT06775470 ·Status: RECRUITING
-
Screening Women at High Genetic Risk for Ovarian Cancer
NCT00033488 ·Status: COMPLETED ·Phase: NA
-
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01080521 ·Status: COMPLETED
-
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
NCT04204811 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472 ·Status: COMPLETED
-
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer
NCT00039559 ·Status: UNKNOWN ·Phase: NA
-
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
NCT00443196 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy
NCT02686463 ·Status: UNKNOWN ·Phase: NA
-
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
NCT04402333 ·Status: UNKNOWN
-
PARPi and Ovarian Cancer Survival
NCT06838429 ·Status: NOT_YET_RECRUITING
-
Quality-of-Life Assessment in Patients With Ovarian Cancer
NCT00003772 ·Status: COMPLETED
-
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT00582205 ·Status: TERMINATED ·Phase: PHASE2
-
Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer
NCT00003695 ·Status: COMPLETED ·Phase: PHASE3
-
Ovarian Reserve After Cancer: Longitudinal Effects
NCT02467231 ·Status: ACTIVE_NOT_RECRUITING
-
EC17 for Intraoperative Imaging in Occult Ovarian Cancer
NCT02000778 ·Status: COMPLETED ·Phase: PHASE1
-
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
NCT03943173 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
NCT02082470 ·Status: COMPLETED ·Phase: NA
-
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
NCT04752865 ·Status: UNKNOWN